Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA
I3LUNG
A European research consortium building explainable AI decision support for metastatic lung cancer.
What they do
I3LUNG, led by IRCCS Istituto Nazionale dei Tumori in Milan, is validating a multimodal AI platform that predicts immunotherapy outcomes in metastatic non-small cell lung cancer, with a prospective trial across six international centers.
The record
- Vertical
- Oncology
- Sub-segment
- Multimodal AI decision support
- Product type
- Platform software
- Stage
- Growth
- Headquarters
- Milan, Italy
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
Who Is Liable When AI Clinical Decision Support Gives Bad Advice?
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
AI reading of prostate MRI is moving from research validation into daily radiology workflow
AI reading of prostate MRI is moving from research validation into daily radiology workflow
Dr. Dereck Mush, MD, MBA
The Chart Is the Channel: What OpenEvidence Inside NYU Langone's Epic Means for Clinical AI
Dr. Dereck Mush, MD, MBA